ARVN
ArvinasยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
ARVN Profile
Arvinas, Inc.
A clinical-stage biotechnology company that developing therapies to degrade disease-causing proteins
5 Science Park, 395 Winchester Ave., New Haven, Connecticut 06511
--
Arvinas, Inc., was incorporated in February 2013 under the laws of the State of Delaware. The company is a biopharmaceutical company dedicated to improving the lives of patients with debilitating and life-threatening diseases by discovering, developing and commercializing treatments to reduce disease-causing proteins. The company uses their proprietary technology platform to design proteolysis for chimeras, or PROTACs, which are designed to utilize the body's own natural protein processing system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas Holding Company, LLC believes that their targeted protein degradation approach is a new therapeutic modality that may offer unique advantages over existing modalities, including traditional small molecule therapies and gene-based medicines.
